Fibrinogen and carotid intima media thickness determine fibrin density in different atherosclerosis extents

Abstract

[1] Bakris G. Are there effects of renin-angiotensin system antagonists beyond blood pressure control? Am J Cardiol 2010;105:21A–9A. [2] Lee KH, Jeong MH, Ahn YK, et al. Gender differences of success rate of percutaneous coronary intervention and short term cardiac events in Korea Acute Myocardial Infarction Registry. Int J Cardiol 2008;130:227–34. [3] Mariat C, Alamartine E, Berthoux F. Measured and estimated glomerular filtration rate. N Engl J Med 2006;355:1068–9 [author reply 1069-70]. [4] Kushner FG, HandM, Smith Jr SC, et al. 2009 focused updates: ACC/AHAGuidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009;120:2271–306. [5] Anderson JL, Adams CD, Antman EM, et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:e426–579. [6] Pitt B, Fonarow GC, Gheorghiade M, Deedwania PC, Duprez DA. Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade. Am J Cardiol 2006;97:26F–33F. [7] Dickstein K, Kjekshus J, Group OSCotOS. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial inMyocardial Infarctionwith Angiotensin II Antagonist Losartan. Lancet 2002;360:752–60. [8] AnavekarNS,McMurray JJ, Velazquez EJ, et al. Relationbetween renal dysfunction and cardiovascular outcomesaftermyocardial infarction.N Engl JMed2004;351:1285–95. [9] Brosius III FC, Hostetter TH, Kelepouris E, et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney and Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Circulation 2006;114:1083–7. [10] Epstein BJ, Smith SM, Choksi R. Recent changes in the landscape of combination RAS blockade. Expert Rev Cardiovasc Ther 2009;7:1373–84. [11] Shewan LG, Coats AJ. Ethics in the authorship and publishing of scientific articles. Int J Cardiol 2011;153:239–40.